Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ERp72 CRISPR/Cas9 KO Plasmid (h): sc-402689
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ERp72 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ERp72 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ERp72 Antibody (B-4): sc-390530
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ERp72 CRISPR/Cas9 KO Plasmid (h) | sc-402689 | 20 µg | $397.00 |
Overview
PDIA4 encodes ERp72, an endoplasmic reticulum (ER)–resident protein disulfide isomerase family member that catalyzes thiol–disulfide exchange reactions to support oxidative folding and quality control of secreted and membrane proteins. ERp72 functions within the ER proteostasis network alongside chaperones and other PDIs, contributing to unfolded protein response (UPR) signaling, ER-associated degradation (ERAD), and maintenance of redox homeostasis under conditions of ER stress. By shaping the maturation of client proteins and limiting proteotoxic stress, PDIA4 influences pathways linked to secretion, antigen processing, and cellular adaptation to perturbations in protein folding. Dysregulated ER folding capacity and chronic ER stress are implicated in cancer biology, metabolic disease, and neurodegenerative processes, making PDIA4 a useful node for mechanistic studies of stress signaling and proteome quality control.
ERp72 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PDIA4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PDIA4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PDIA4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ERp72 protein expression.
This CRISPR knockout system enables efficient generation of PDIA4-deficient cell models for investigation of ERp72 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PDIA4 exon(s) critical for ERp72 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PDIA4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ERp72 CRISPR/Cas9 KO Plasmid (h) and ERp72 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PDIA4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ERp72 HDR Plasmid (h) and ERp72 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PDIA4 homology arms to support homology-directed repair at defined PDIA4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.